Working… Menu

Biomarkers of Insufficient Sleep and Sleepiness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03130803
Recruitment Status : Completed
First Posted : April 27, 2017
Last Update Posted : April 17, 2019
University of Colorado, Denver
Information provided by (Responsible Party):
Kenneth Wright, University of Colorado, Boulder

Brief Summary:
Sleep and wakefulness disorders impact 50 to 70 million Americans and insufficient sleep is epidemic with over 50% of Americans reporting less than 7 hours of sleep per night. Health problems associated with insufficient sleep include inflammation, depression and anxiety, diabetes, stress, drug abuse, poor quality of life, obesity, and fatigue related accidents on the job/while driving. While the contribution of sleep to overall health, well-being, and public safety is recognized, no established clinical biomarkers of sleep deficiency exist. Such biomarkers would have utility as road-side biomarkers of sleepiness (e.g., drowsy driving), monitoring on the job fatigue/fitness for duty (e.g., transportation, military ops health care), monitoring sleep health, as well as for clinical diagnostics and measures of clinical treatment outcomes. Thus, investigators designed a controlled laboratory insufficient sleep protocol utilizing metabolomics to identify biomarkers of insufficient sleep. Investigators propose to identify changes in metabolites that consistently occur during insufficient sleep. As an exploratory outcome investigators will examine associated changes in metabolites and cognitive performance during insufficient sleep.

Condition or disease Intervention/treatment Phase
Sleep Deprivation Insufficient Sleep Syndrome Sleep Wake Disorders Behavioral: Insufficient Sleep Not Applicable

Detailed Description:
Impaired sleep affects millions of people each year representing an important public health issue. This project will utilize metabolomics approaches to identify biomarkers in the blood that respond consistently to insufficient sleep. The overall goal of this project is to use a discovery and targeted approach to identify specific small molecules in plasma as candidate biomarkers of insufficient sleep. Investigators will conduct a controlled in-laboratory insufficient sleep protocol where participants receive 2 days of 5 hour sleep opportunities per night on 2 separate occasions. Plasma will be collected for metabolomics analyses every 2 hours (across 24 hours) during scheduled wakefulness at baseline and during insufficient sleep. Participants will complete the insufficient sleep protocol twice, separated by 23 days of sufficient sleep, to identify which plasma metabolites consistently change during insufficient sleep. Investigators anticipate these findings will be the first step in establishing validated biomarkers of impaired sleep that will advance our understanding, assessment and management of health consequences and symptoms associated with insufficient sleep.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Biomarkers of Insufficient Sleep and Sleepiness
Study Start Date : October 2016
Actual Primary Completion Date : February 22, 2019
Actual Study Completion Date : February 22, 2019

Arm Intervention/treatment
No Intervention: Baseline
9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
Experimental: Insufficient Sleep
2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
Behavioral: Insufficient Sleep
2 days with 5 hour sleep opportunity per day

Primary Outcome Measures :
  1. Plasma Metabolomics Biomarker Fingerprint [ Time Frame: Plasma will be collected for metabolomics analyses every 2 hours during scheduled wakefulness at baseline and during the final 24 hours of insufficient sleep for both visits one and two ]
    Investigators can detect ~4,000 plasma metabolites and will identify which metabolites have consistent, sensitive, and specific responses to insufficient sleep across visits one and two. These metabolites will be identified as candidate biomarkers of insufficient sleep.

Secondary Outcome Measures :
  1. Psychomotor Vigilance Test [ Time Frame: Participants will complete the psychomotor vigilance test every 3 hours during scheduled wakefulness across baseline and insufficient sleep for visits one and two ]
    The Psychomotor Vigilance Test is a reaction time based test designed to evaluate the ability to sustain attention.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • normal Body mass index (18.5-24.9)
  • normal blood chemistries
  • habitual sleep duration ~7 - 9.25 hours
  • live at Denver altitude or higher for at least 3 months

Exclusion Criteria:

  • must not be participating in another research study that could influence safe participation in the current study
  • any clinically significant medical or surgical condition within last year
  • clinically significant abnormality during physical examination
  • any physician determined significant abnormality in vital signs, EKG, or clinical laboratory values
  • any clinically significant psychiatric condition defined by DSM-V
  • any clinically significant sleep disorder
  • use of medications/supplements/drugs within one month of study or need of medications during study
  • symptoms of active illness
  • uncorrected visual impairment
  • working shift-work in year prior to study
  • travel more than 1 time zone in 3 weeks prior to study
  • pregnant/nursing
  • greater than moderate caffeine or alcohol use
  • positive toxicology screening
  • current smoker

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03130803

Layout table for location information
United States, Colorado
Sleep and Chronobiology Laboratory
Boulder, Colorado, United States, 80309
Sponsors and Collaborators
University of Colorado, Boulder
University of Colorado, Denver
Layout table for investigator information
Principal Investigator: Kenneth P Wright, PhD University of Colorado, Boulder

Layout table for additonal information
Responsible Party: Kenneth Wright, Professor, University of Colorado, Boulder Identifier: NCT03130803     History of Changes
Other Study ID Numbers: R01HL132150 ( U.S. NIH Grant/Contract )
First Posted: April 27, 2017    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Any data generated from the proposed work that is presented in a peer reviewed journal will be uploaded, de-identified, into the Metabolomics Data Repository and Coordinating Center (DRCC) (U01) through UCSD; In addition, .raw data that is presented in a peer reviewed journal will be archived indefinitely and made available upon request.
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Deprivation
Sleep Wake Disorders
Signs and Symptoms
Nervous System Diseases
Neurologic Manifestations
Mental Disorders